Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Miransertib × Clear all

Phase

Status

Completed 2 Terminated 1 Recruiting 1 No longer available 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

pembrolizumab 571 Specimen Handling 483 Carboplatin 454 Magnetic Resonance Spectroscopy 436 Cisplatin 408 Cyclophosphamide 404 Radiotherapy 357 Gemcitabine 315 Bevacizumab 313 Paclitaxel 301 Biopsy 287 Drug Therapy 285 Blood Specimen Collection 252 Nivolumab 237 venetoclax 230 Capecitabine 229 Oxaliplatin 227 fludarabine 224 Injections 211 Docetaxel 209 Fluorouracil 198 Dexamethasone 190 Radiosurgery 177 Rituximab 161 Pemetrexed 161 Standard of Care 158 atezolizumab 149 Surgical Procedures, Operative 148 durvalumab 147 130-nm albumin-bound paclitaxel 138

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-04-17

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡